Trial reportMedicine2025
Efficacy and safety of Cyperus rotundus extract on weight management in obese individuals: A randomized, double-blind, placebo-controlled study.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Piceatannol ameliorates intestinal barrier dysfunction in urosepsis by modulating the Nrf2/ROS/NF-κB pathway.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity, a critical public health issue, is linked to numerous metabolic and cardiovascular disorders. Natural products may present a safer and more holistic approach to weight management. A standardized extract of Cyperus rotundus (CRE), containing 6% to 8% stilbenes (scirpusin A, scirpusin B, and piceatannol) was effective in reducing adipogenesis and weight gain in preclinical studies. This study aimed to assess the efficacy and safety of CRE combined with the bioavailability enhancer piperine (CREP), as a natural supplement for managing weight in obese individuals.
methodsA randomized, double-blind, placebo-controlled trial was conducted over 90 days involving 96 obese participants. Subjects received oral supplementation of 500 mg CRE with 5 mg piperine (CREP) twice daily, alongside a prescribed exercise and diet regimen. Primary outcomes included anthropometric measures such as body weight, body mass index, waist circumference, hip circumference, and waist-hip ratio. Secondary outcomes assessed included serum lipid parameters, Apolipoprotein B-100, calorie intake, physical activity, and safety evaluations.
resultsCREP supplementation led to significant reductions in body weight, body mass index, waist, and hip circumference compared to placebo. Improvements in serum lipid profiles and Apolipoprotein B-100 levels were also observed in the CREP group. No adverse events were reported, and all laboratory parameters remained within normal ranges.
conclusionThe findings demonstrate that CREP is a safe and effective natural supplement for reducing abdominal obesity and improving lipid profiles. The observed benefits surpassed those of lifestyle management alone, supporting the potential development of CREP as a natural therapeutic option for weight management in obese individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.